← Back to patent-cliff list
[225Ac]Ac-FL-261
Tier C — Watch / trade[225Ac]Ac-FL-261
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：c-Met
Indications (approved)：Solid tumour, Non-small cell lung cancer
Regional status
US
Phase I
2026-09-09
EU
-
China
Phase III
2026-09-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [225Ac]Ac-FL-261?
Approved indications include: Solid tumour, Non-small cell lung cancer.
When does the [225Ac]Ac-FL-261 patent expire?
No public expiry year is available for [225Ac]Ac-FL-261 yet; this page updates once verified.
How do I get a quote for [225Ac]Ac-FL-261 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28